EPIGENESISPHARMACEUTICALS.COM

Serial Number 76360212
606

Registration Progress

Application Filed
Jan 7, 2002
Under Examination
Jul 1, 2003
Approved for Publication
Mar 19, 2003
Published for Opposition
Apr 8, 2003
Registered

Trademark Image

EPIGENESISPHARMACEUTICALS.COM

Basic Information

Serial Number
76360212
Filing Date
January 7, 2002
Published for Opposition
April 8, 2003
Abandonment Date
July 2, 2006
Drawing Code
1000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jul 2, 2006
Classes
005

Rights Holder

EPIGENESIS PHARMACEUTICALS LLC

03
Address
7 CLARKE DRIVE
CRANBURY, NJ 08512

Ownership History

EPIGENESIS Pharmaceuticals, Inc.

Original Applicant
03
Cranbury, NJ

EPIGENESIS Pharmaceuticals, Inc.

Owner at Publication
03
Cranbury, NJ

EPIGENESIS PHARMACEUTICALS LLC

New Owner After Publication #1
03
CRANBURY, NJ

Legal Representation

Attorney
Viviana Amzel, Esq.

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

31 events
Date Code Type Description Documents
Sep 7, 2006 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Sep 7, 2006 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Dec 29, 2005 EEXT I TEAS EXTENSION RECEIVED Loading...
Dec 29, 2005 EXT5 S EXTENSION 5 FILED Loading...
Dec 29, 2005 EX5G S EXTENSION 5 GRANTED Loading...
Jul 1, 2005 EEXT I TEAS EXTENSION RECEIVED Loading...
Jul 1, 2005 EXT4 S EXTENSION 4 FILED Loading...
Jul 1, 2005 EX4G S EXTENSION 4 GRANTED Loading...
Jan 10, 2005 EX3G S EXTENSION 3 GRANTED Loading...
Dec 23, 2004 EEXT I TEAS EXTENSION RECEIVED Loading...
Dec 23, 2004 EXT3 S EXTENSION 3 FILED Loading...
Jul 28, 2004 EX2G S EXTENSION 2 GRANTED Loading...
Jul 19, 2004 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jul 16, 2004 MAIL I PAPER RECEIVED Loading...
Jul 12, 2004 CFIT O CASE FILE IN TICRS Loading...
Jun 30, 2004 EEXT I TEAS EXTENSION RECEIVED Loading...
Jun 30, 2004 EXT2 S EXTENSION 2 FILED Loading...
Jan 22, 2004 EX1G S EXTENSION 1 GRANTED Loading...
Dec 31, 2003 EEXT I TEAS EXTENSION RECEIVED Loading...
Dec 31, 2003 EXT1 S EXTENSION 1 FILED Loading...
Jul 1, 2003 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 8, 2003 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 19, 2003 NPUB O NOTICE OF PUBLICATION Loading...
Jan 29, 2003 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 25, 2002 MAIL I PAPER RECEIVED Loading...
Oct 25, 2002 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 25, 2002 1.AD I SEC. 1(A) CLAIM DELETED Loading...
Oct 25, 2002 1.BA I Sec. 1(B) CLAIM ADDED Loading...
Apr 26, 2002 CNRT F NON-FINAL ACTION MAILED Loading...
Apr 8, 2002 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 4, 2002 DOCK D ASSIGNED TO EXAMINER Loading...

Detailed Classifications

Class 005
medical diagnostic and therapeutic preparations and devices for administering same, sold filled with diagnostic and therapeutic preparations or separately as a kit, all for administration via diverse routes of administration, including through the respiratory airways, and medical devices for administering the pharmaceuticals, sold filled or separately as a kit, the preparations including polynucleotides, proteins and/or organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small organic and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms,; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, Acute Respiratory Distress Syndrome (ARDS), renal damage and failure, ischemia, resulting from the administration of certain drugs, including adenosine stress tests, infantile Respiratory Distress Syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, e.g., colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc., as well as all metastatic cancers, e.g.; cancers which metastasized to the lung(s), breast, liver and prostate included
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Pseudo Mark
EPI GENESIS PHARMACEUTICALS DOT COM

Classification

International Classes
005